Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Statins Potentiate Aminopeptidase Inhibitor (pro)Drug Activity in Acute Myeloid Leukemia Cells

Jacqueline Cloos, PhD, Godefridus J Peters, PhD, Marjon Al, BSc, Yehuda G Assaraf, PhD, Lixia Wang, PhD, Jack W. Singer, MD, Jorge E. Cortes, MD, Gert J. Ossenkoppele, MD PhD, Gerrit Jansen, PhD

Blood (2018) 132 (Supplement 1): 3945.

https://doi.org/10.1182/blood-2018-99-114447

Published: 2018

Journal Articles

Results of a Phase 3 Randomised Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Not Eligible for Stem Cell Transplantation

Gilles Andre Salles, Wojciech Jurczak, David J. Andorsky, MD, Donald P. Quick, MD, Jack W. Singer, MD, Simran Bedi Singh, Lixia Wang, PhD, Anton Egorov, MD, Christine Gabarroca, MSc, Ruth Pettengell, MD

Blood (2018) 132 (Supplement 1): 4189.

https://doi.org/10.1182/blood-2018-99-112455

Published: 2018

Journal Articles

Safety of Split First Dosing Vs Standard Dosing Administration of Daratumumab Among Multiple Myeloma Patients Treated in a US Community Oncology Setting: A Real-World Observational Study

Robert M Rifkin, MD, David Singer, PharmD, Kathleen M. Aguilar, MPH, Bismark Baidoo, PhD, Eric M Maiese, PhD

Blood (2018) 132 (Supplement 1): 4846.

https://doi.org/10.1182/blood-2018-99-116808

Published: 2018

Journal Articles

Phase II Clinical Study of the Clinical Efficacy and Safety of Tosedostat in Patients with Myelodysplastic Syndromes (MDS) after Failure of Hypomethylating Agent-Based Therapy

Sangmin Lee, MD, Pinkal Desai, MDMPH, Bianca Edirisinghe, Samantha Pianello, Jack W. Singer, MD, Michael Samuel, MD, Ellen K Ritchie, MD, Gail J. Roboz, MD

Blood (2017) 130 (Supplement 1): 2966.

https://doi.org/10.1182/blood.V130.Suppl_1.2966.2966

Published: 2017

Journal Articles

A Selective ORAL GLYT1 Inhibitor, Improves Anemia and RED CELL Survival in a MOUSE MODEL of Beta-Thalassemia

Carlo Brugnara, MD, Anja Harmeier, Lucia De Franceschi, MD, Alessandro Matte, Michael Winter, Annette Koerner, Omar Khwaja, Thomas Singer, Elisabetta Beneduce, Enrica Federti, Angela Siciliano

Blood (2016) 128 (22): 1284.

https://doi.org/10.1182/blood.V128.22.1284.1284

Published: 2016

Journal Articles

Risk of Non-Melanoma Skin Cancer Following Hematopoietic Cell Transplantation and Voriconazole-Associated Risk

Lawrence F. Kuklinski, BA, Shufeng Li, MS, Margaret R. Karagas, PhD, Bernice Y. Kwong, MD, Wen-Kai Weng, MD PhD

Blood (2016) 128 (22): 2249.

https://doi.org/10.1182/blood.V128.22.2249.2249

Published: 2016

Journal Articles

Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts <100,000/µl

Blood (2016) 128 (22): LBA-5.

https://doi.org/10.1182/blood.V128.22.LBA-5.LBA-5

Published: 2016

Journal Articles

Using the Zebrafish to Model the Tumour-Suppressor Effects of NUP98 in NUP98-NSD1 mediated AML

Corey Filiaggi, BScH, Vinothkumar Rajan, B.Tech, Sergey Prykhozhij, PhD, Adam P Deveau, BScH, MSc, Jason N. Berman, MD

Blood (2016) 128 (22): 5117.

https://doi.org/10.1182/blood.V128.22.5117.5117

Published: 2016

Journal Articles

Relationship of JAK2 V617F Allelic Burden (AB) to Demographics, Disease Characteristics, and Response to Therapy in Persist-1, a Randomized Phase III Study of Pacritinib (PAC) Versus Best Available Therapy (BAT) in Patients (pts) with Primary and Secondary Myelofibrosis (MF)

Alessandro M. Vannucchi, Adam Mead, Miklos Egyed, Anita Szoke, Aleksandr Suvorov, Andrew Perkins, Jiri Mayer, Peter Ganly, Harry C. Schouten, Patrizia Tosi, Charles Michael Farber, Pierre Zachee, Jean-Jacques Kiladjian, Jyoti Nangalia, James P. Dean, Huafeng Zhou, Jack W. Singer, Ruben A. Mesa, Claire N. Harrison

Blood (2016) 128 (22): 3131.

https://doi.org/10.1182/blood.V128.22.3131.3131

Published: 2016

Journal Articles

Pacritinib Targets IRAK1 and Shows Synergy with HDAC and BET Inhibitors in Acute Myeloid Leukemia

Alka Puri, PhD, Shawn Mahmood, B.S., B.A., Bernadette Maertens, Monika Davare, PhD, Stephen E Kurtz, PhD, Cristina E. Tognon, Christopher O. Eden, BA, Johannes Elferich, PhD, Ujwal Shinde, PhD, Brian J. Druker, MD, Jack W. Singer, Anupriya Agarwal

Blood (2016) 128 (22): 3514.

https://doi.org/10.1182/blood.V128.22.3514.3514

Published: 2016

Journal Articles

Singer K, Fisher B. Studies on abnormal hemoglobins, VI: electrophoretic demonstration of type S (sickle cell) hemoglobin in erythrocytes incapable of showing the sickle cell phenomenon. Blood . 1953;8(3): 270-275 .

Blood (2016) 127 (7): 791.

https://doi.org/10.1182/blood-2015-12-688135

Published: 2016

Journal Articles

Singer K, Bornstein FP, Wile SA. Thrombotic thrombocytopenic purpura. Blood . 1947;2(6): 542-554 .

Blood (2016) 127 (2): 169.

https://doi.org/10.1182/blood-2015-11-684308

Published: 2016

Journal Articles

Targeting JAK2 By Gene Knockout or Pacritinib Treatment Reduces Gvhd and Xenograft Rejection By Promoting Induced Treg Differentiation

Brian C Betts, MD, David Bastian, Hung Nguyen, PhD, Jessica Lauren Heinrichs, BS, MS, Yongxia Wu, MD PhD, Anandharaman Veerapathran, PhD, Marie C Lee, MD, Jack Singer, MD, Claudio Anasetti, MD, Xue-Zhong Yu, MD MS

Blood (2015) 126 (23): 1874.

https://doi.org/10.1182/blood.V126.23.1874.1874

Published: 2015

Journal Articles

Pacritinib, a Dual FLT3/JAK2 Inhibitor, Reduces Irak-1 Signaling in Acute Myeloid Leukemia

Megan M Cleary, B.S., B.A., Rhese Thompson, Shawn Mahmood, B.S., B.A., Monika Davare, PhD, Steve Kurtz, PhD, Johannes Elferich, PhD, Ujwal Shinde, PhD, Brian J. Druker, MD, Jack Singer, MD, Anupriya Agarwal, PhD

Blood (2015) 126 (23): 570.

https://doi.org/10.1182/blood.V126.23.570.570

Published: 2015

Journal Articles

A Randomized Phase II Study of Tosedostat in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Raya Mawad, MD, Pamela S. Becker, MD PhD, Paul C. Hendrie, MD PhD, Bart L Scott, MD, Brent L. Wood, MD PhD, Carol Dean, MPH, BSN, Vicky Sandhu, MD MPH, H. Joachim Deeg, MD, Roland B. Walter, MD PhD MS, Lixia Wang, PhD, Jack Singer, MD, Elihu H. Estey, MD, John Pagel, MD PhD

Blood (2014) 124 (21): 3690.

https://doi.org/10.1182/blood.V124.21.3690.3690

Published: 2014

Journal Articles

Distinct Associations Between UGT1A1 Gene Promoter Polymorphism and Hyperbilirubinemia in Korean CML Patients Treated with Nilotinib and Radotinib

Soo-Hyun Kim, Soo Young Choi, Sung-Eun Lee, Yun Jeong Oh, Hae Lyun Yoo, Eun-Jung Jang, Mi-yeon Choi, Moon-mi Jang, Hyeoung Joon Kim, MD, Jae-Yong Kwak, MD PhD, Hawk Kim, MD, PhD., Young-Rok Do, PhD, Dong-Wook Kim, MD PhD

Blood (2014) 124 (21): 5511.

https://doi.org/10.1182/blood.V124.21.5511.5511

Published: 2014

Journal Articles

Comprehensive Kinase Profile of Pacritinib, a Non-Myelosuppressive JAK2 Kinase Inhibitor in Phase 3 Development in Primary and Post ET/PV Myelofibrosis

Jack Singer, MD, Suliman Al-Fayoumi, PhD MBA, Haiching Ma, Rami S Komrokji, MD, Ruben Mesa, MD, Srdan Verstovsek, MD PhD

Blood (2014) 124 (21): 1874.

https://doi.org/10.1182/blood.V124.21.1874.1874

Published: 2014

Journal Articles

A Phase II Study Of Tosedostat (TST) In Combination With Either Cytarabine Or Decitabine In Newly Diagnosed Older Patients With Acute Myeloid Leukemia (AML) Or High-Risk Myelodysplastic Syndrome (MDS)

Raya Mawad, MD, Pamela S. Becker, MD, PhD, Paul C. Hendrie, MD, PhD, Bart L Scott, MD, Brent L. Wood, MD, PhD, Carol Dean, RN, Ravinder K Sandhu, MD, H. Joachim Deeg, MD, Roland B. Walter, MD, PhD, Frederick R. Appelbaum, MD, Lixia Wang, PhD, Han Myint, MD, Jack Singer, MD, Elihu H. Estey, MD, John M. Pagel, MD, PhD

Blood (2013) 122 (21): 3926.

https://doi.org/10.1182/blood.V122.21.3926.3926

Published: 2013

Journal Articles

Targeting Aminopeptidases by Tosedostat (TST) (CHR2797), Alone and with LBH589, Induces Significant Cytotoxicity Against Human Multiple Myeloma (MM) Cells

Chirag Acharya, Mike Y Zhong, B.S., Daniel Tannenbaum, B.S., Michelle Chen, Matt Ma, Jack Singer, MD, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Yu-Tzu Tai, PhD

Blood (2012) 120 (21): 1847.

https://doi.org/10.1182/blood.V120.21.1847.1847

Published: 2012

Journal Articles

Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment

Emanuela Salvatorelli, MD, Odalys Gonzalez Paz, PhD, Elvio Covino, MD, Massimo Chello, MD, Jack Singer, MD, Pierantonio Menna, PhD, Giorgio Minotti, MD

Blood (2011) 118 (21): 4966.

https://doi.org/10.1182/blood.V118.21.4966.4966

Published: 2011

NARROW

Statins Potentiate Aminopeptidase Inhibitor (pro)Drug Activity in Acute Myeloid Leukemia Cells

Results of a Phase 3 Randomised Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Not Eligible for Stem Cell Transplantation

Safety of Split First Dosing Vs Standard Dosing Administration of Daratumumab Among Multiple Myeloma Patients Treated in a US Community Oncology Setting: A Real-World Observational Study

Phase II Clinical Study of the Clinical Efficacy and Safety of Tosedostat in Patients with Myelodysplastic Syndromes (MDS) after Failure of Hypomethylating Agent-Based Therapy

A Selective ORAL GLYT1 Inhibitor, Improves Anemia and RED CELL Survival in a MOUSE MODEL of Beta-Thalassemia

Risk of Non-Melanoma Skin Cancer Following Hematopoietic Cell Transplantation and Voriconazole-Associated Risk

Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts <100,000/µl

Using the Zebrafish to Model the Tumour-Suppressor Effects of NUP98 in NUP98-NSD1 mediated AML

Relationship of JAK2 V617F Allelic Burden (AB) to Demographics, Disease Characteristics, and Response to Therapy in Persist-1, a Randomized Phase III Study of Pacritinib (PAC) Versus Best Available Therapy (BAT) in Patients (pts) with Primary and Secondary Myelofibrosis (MF)

Pacritinib Targets IRAK1 and Shows Synergy with HDAC and BET Inhibitors in Acute Myeloid Leukemia

Singer K, Fisher B. Studies on abnormal hemoglobins, VI: electrophoretic demonstration of type S (sickle cell) hemoglobin in erythrocytes incapable of showing the sickle cell phenomenon. Blood . 1953;8(3): 270-275 .

Singer K, Bornstein FP, Wile SA. Thrombotic thrombocytopenic purpura. Blood . 1947;2(6): 542-554 .

Targeting JAK2 By Gene Knockout or Pacritinib Treatment Reduces Gvhd and Xenograft Rejection By Promoting Induced Treg Differentiation

Pacritinib, a Dual FLT3/JAK2 Inhibitor, Reduces Irak-1 Signaling in Acute Myeloid Leukemia

A Randomized Phase II Study of Tosedostat in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Distinct Associations Between UGT1A1 Gene Promoter Polymorphism and Hyperbilirubinemia in Korean CML Patients Treated with Nilotinib and Radotinib

Comprehensive Kinase Profile of Pacritinib, a Non-Myelosuppressive JAK2 Kinase Inhibitor in Phase 3 Development in Primary and Post ET/PV Myelofibrosis

A Phase II Study Of Tosedostat (TST) In Combination With Either Cytarabine Or Decitabine In Newly Diagnosed Older Patients With Acute Myeloid Leukemia (AML) Or High-Risk Myelodysplastic Syndrome (MDS)

Targeting Aminopeptidases by Tosedostat (TST) (CHR2797), Alone and with LBH589, Induces Significant Cytotoxicity Against Human Multiple Myeloma (MM) Cells

Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only